Search

Daiichi Sankyo will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in multiple types of cancer at the 2023 European Society for Medical Oncology (ESMO23) Congress to be held 20-24 Oct 2023. Three late-breaking abstracts, including two Presidential Symposia presentations, are among the more than 20 abstracts showcasing Daiichi Sankyo's leadership and progress in developing new standards of care for patients with cancer. Data at ESMO will highlight results from the TROPION-Breast01 and TROPION-Lung01 phase 3 trials (LBA11 and LBA12) evaluating datopotamab deruxtecan (Dato-DXd) versus chemotherapy in patients with HR positive, HER2 low or negative metastatic breast cancer and advanced non-small cell lung cancer (NSCLC) during back-toback presentations at the Presidential Symposium 3. These data will be featured in an ESMO press briefing. Other late-breaking data includes a mini-oral session featuring the first presentation of progression-free and overall survival results from the DESTINY-PanTumor02 phase 2 trial (LBA34) evaluating ENHERTU (trastuzumab deruxtecan) across multiple HER2 expressing solid tumours, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and other cancers. Updates from other trials across Daiichi Sankyo's DXd ADC portfolio include mini-oral sessions presenting an exploratory analysis of the intracranial efficacy of patritumab deruxtecan (HER3-DXd) in patients with EGFRmutated metastatic NSCLC from the HERTHENA-Lung01 phase 2 trial, and updated data from an ongoing first-inhuman phase 1 trial of raludotatug deruxtecan (R-DXd) in patients with previously treated ovarian cancer. A poster presentation also will feature updated clinical and biomarker results of ifinatamab deruxtecan (I-DXd) in patients with advanced solid tumours from an ongoing phase 1/2 trial. Additional datopotamab deruxtecan data at ESMO includes the first presentation from the TROPION-Lung05 phase 2 trial in patients with previously treated NSCLC with actionable genomic alterations and updated data from the BEGONIA phase 1b/2 trial in patients with previously untreated advanced/metastatic triple negative breast cancer during two mini-oral sessions. Other ENHERTU data to be highlighted in proffered paper or mini-oral sessions include the primary results from the DESTINY-PanTumor01 phase 2 trial in patients with solid tumours with HER2 activating mutations and a pooled analysis from the DESTINY-Lung01 and DESTINY-Lung02 phase 2 trials in patients with HER2 mutant metastatic NSCLC with and without brain metastases. A proffered paper session also will include updated survival results from the DESTINY-Breast04 phase 3 trial in patients with HER2 low metastatic breast cancer as well as pooled exploratory efficacy and safety analysis from the DESTINY-Breast01, DESTINY-Breast02 and DESTINYBreast03 trials in patients with HER2 positive metastatic breast cancer with brain metastases. Original source: Daiichi Sankyo Co Ltd, website: http://www.daiichisankyo.com/, Copyright Daiichi Sankyo Company Limited 2023., research and development; anticancer drugs; datopotamab deruxtecan; ENHERTU; ifinatamab deruxtecan; monoclonal antibodies; therapeutic antibodies; trastuzumab deruxtecan; Daiichi [...]

The article focuses on the worse outcomes experienced by younger colorectal cancer patients with metastatic disease compared to older patients. It further discusses the study found that younger patients had distinct patterns of adverse events and lower survival rates. Furthermore, genomic data suggested that different genetic profiles may contribute to the poorer outcomes in early-onset colorectal cancer; and highlighting the need for individualized treatment approaches.

A new analysis published in Clinical Cancer Research suggests that patients with treatment-refractory cancers who did not meet eligibility criteria for a pan-cancer clinical trial but received waivers allowing them to participate had similar outcomes to patients who participated without waivers. The study highlights the potential benefits of broadening eligibility criteria for clinical trials. However, it remains unclear how increasing trial inclusivity might impact treatment safety and efficacy. The study had limitations, including the small sample size of waiver-granted patients, and experts caution against overemphasizing efficacy based on the results. [Extracted from the article]

A study published in JAMA Oncology found that patients with metastatic or advanced cancer who received systemic care in the last two weeks of life did not have longer survival rates compared to those who received low rates of such care. The study, which used data from the Flatiron Health electronic health records database, included 78,446 adults with advanced or metastatic cancer. The findings suggest that oncologists should focus more on honest communication with patients about their choices rather than providing systemic anticancer therapy at advanced stages of cancer. The study also challenges the widely adopted cancer quality metric that focuses on systemic treatment within 14 days of death. [Extracted from the article]

The article discusses a study published in "JAMA Oncology" which reviewed data from adult cancer survivors who participated in the National Survey of Drug Use and Health (NSDUH) between 2015 and 2020. Topics include cancer survivors with the highest rates of substance use disorders (SUDs,) most common SUD, and limitations and implications.

Byline: By, Rachael Davis Putting pen to paper and writing a physical letter isn't a particularly common occurrence in modern life. We're far more likely to drop someone a text [...]

New Consensus Paper Published in Nature Medicine by 35 Members of Bloomberg New Economy International Cancer Coalition East-West collaboration argues that post-pandemic, telemedicine and remote monitoring can deliver better cancer [...]

The article discusses how breast cancer patients face treatment and isolation and amid the pandemic. It mentions that having cancer during pandemic meant facing a unique sort of isolation. It reveals that the number of people coming in for routine annual screenings, including mammograms, declined during the pandemic.

The article discusses research by Saro Aprikian and colleagues, reported in the BMJ Supportive & Palliative Care issue, on the effectiveness of medicinal cannabis in reducing cancer-related pain in adult cancer patients. The study found that physician-prescribed cannabis, particularly cannabinoids, led to significant reductions in pain scores, supporting its use as an adjunct pain relief strategy and potentially reducing the need for other medications such as opioids in cancer patients.

The article discusses research by Vishal Patel and colleagues, reported in the May 11, 2023, issue of "JAMA Oncology." Topics include the increasing number of cancer survivors experiencing functional limitations, the higher prevalence of functional limitation among survivors of certain cancers, and the need to address the quality of life and functionality of cancer survivors.

NEW YORK, NY -- The following information was released by NYC Health + Hospitals: With more than 250 Community Health Workers, NYC Health + Hospitals has built one of the [...]

NASHVILLE, Tenn.--(BUSINESS WIRE)--Jul 30, 2024-- https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Freimaginecare.com%2F&esheet=54100631&newsitemid=20240730802480&lan=en-US&anchor=Reimagine+Care&index=1&md5=42442ea8e71bfb0fd866b16f1419f0cc has published a groundbreaking https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Freimaginecare.com%2Fpublications%2Fthe-reimagine-care-effect%2F&esheet=54100631&newsitemid=20240730802480&lan=en-US&anchor=study&index=2&md5=913b727e05ace83d34415047924aa0d5 aimed at transforming the management of symptoms and side effects associated with cancer treatment. The organization is dedicated to […]

LOS ANGELES, CA -- The following information was released by UCLA Health System: Chaplain accompanies Debra Ball on spiritual, emotional roller coaster. Debra Ball was losing faith. Battling metastatic breast [...]

2024 AUG 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Oncology - Lung Cancer. According to news reporting [...]

Byline: Letters to the Editor SIR -- I'm confused by those former Conservative voters swarming to Reform UK. In doing so they will only hand Labour an even larger majority [...]

NASHVILLE, Tenn. -- The following information was released by Vanderbilt University: A team of Vanderbilt researchers has developed a wirelessly activated device that mimics the wavelike muscular function in the [...]

WASHINGTON -- The following information was released by the Cato Institute: Jeffrey A. Singer In a March 22 opinion column in the New York Times entitled 'The DEA Needs to [...]

Byline: By, Caroline Jones When somebody as prominent as King Charles is diagnosed with cancer, it can lead many of us to question any health niggles we have and wonder [...]

2024 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- In a first-ever human clinical trial of four adult patients, [...]

AstraZeneca advances its lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), held in Singapore from [...]

2024 FEB 14 (VerticalNews) -- By a News Reporter-Staff News Editor at Education Letter -- A new study on Nursing - Oncology Nursing is now available. According to news reporting [...]

(GLOBE NEWSWIRE via COMTEX) -- - Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with [...]

BASKING RIDGE: DAIICHI SANKYO has issued the following news release: Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in multiple types [...]

Byline: By, Courtney Pochin Five years ago, Dr Anisha Patel was diagnosed with stage 3 rectal cancer -and ever since, her life hasn't been the same. Though she is in [...]

Byline: By, Lucy Williamson A 16-year-old boy found out he has aggressive cancer after suffering stomach ache just before his GCSE exam. Ross Long, now 26, first work up with [...]

Launching the Jammu and Kashmirs first ever state-of-of-art Tata Memorial Center(TMC) Mumbai in the new block of Govt Medical College Kathua, Union Minister of State (Independent Charge) Science & Technology; [...]

NEW DELHI, India -- The following information was released by the Government of India: Launching the Jammu and Kashmir's first ever state-of-of-art Tata Memorial Center(TMC) Mumbai in the new block [...]

Byline: James Le Fanu The Surgery Britain, it is reassuring to know, is rated the best place in the world to die. We are top of the league of 80 [...]

Algorithm designed to predict and better distribute work among cancer patient navigators PEORIA, Ill. , June 23, 2023 /PRNewswire/ -- A cancer diagnosis can be overwhelming. Nurse navigators offer much-needed [...]

(GLOBE NEWSWIRE via COMTEX) -- - Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early [...]

Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach BOSTON, LAUSANNE, Switzerland and [...]

(GLOBE NEWSWIRE via COMTEX) -- Ad hoc announcement pursuant to Art. 53 LR - Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET [...]

2023 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on esophageal stenosis have been published. According to news reporting from Sibiu, [...]

2023 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on dyspnea have been presented. According to news originating from Seattle, [...]

London: HealthBeacon PLC has issued the following press release: HealthBeacon PLC on Wednesday said it was deploying its 'global patient safety technology platform' across the NHS and pharmaceutical industry in [...]

Byline: JUDY PACKER-TURSMAN Specific pre-existing health conditions, and their combinations, in older people make it likelier they could die after breaking a bone -- a much greater risk than either [...]

Byline: By, Will Stewart Vladimir Putin's top Russian diplomat has responded to speculation over the president's health saying no 'sane person can suspect any signs of an illness or ailment'. [...]

2023 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Cancer have been published. According to news originating from [...]

2023 JAN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Oncology - Esophageal Cancer have been published. According to [...]

CAMBRIDGE: Foundation Medicine has issued the following news release: Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present 14 [...]

BOSTON, MA -- The following information was released by the Massachusetts General Hospital (MGH): Key Takeaways It's important to make sure patients are engaged in their care including whether it [...]

London: University of Surrey has issued the following news release: More than 70 percent of patients with bowel cancer are not diagnosed using official screening programmes meaning diagnoses are often [...]

It affects us all. And since we have only one health, it is up to each of us to take care of it and at the same time help those [...]

NEW YORK: Bloomberg Media has issued the following news release: The Bloomberg New Economy International Cancer Coalition (the 'Coalition') today called for a permanent paradigm change in the way cancer [...]

Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational [...]

Byline: Claudia Rowan This time last year, Britain had just completed a second national lockdown and was preparing for a Christmas in tiers. Cancer patients were enduring a desperately lonely [...]